Wed, Oct 1, 2014, 4:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Yahoo! Inc. (YHOO) Message Board

left2rightdoor 72 posts  |  Last Activity: 17 minutes ago Member since: Jul 16, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Something is going on. Vaccine restart, recognition of Ebola DNA delivery? HSV news?

  • Vical Incorporated (Nasdaq:VICL) announced today that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine.
    The Phase 1, randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and conducted at the NIH Clinical Center. The data were presented at the American Society for Microbiology (ASM) 2006 Biodefense Research Meeting in Washington, D.C., by Julie E. Martin, D.O., a trial investigator and research scientist at NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC), which developed the vaccine. The DNA vaccine used in the Phase 1 trial incorporates genetic material encoding core and surface proteins from two strains of Ebola. Vical has secured a nonexclusive license from the NIH to proprietary gene sequences used in the vaccine.

  • Reply to

    CDC antiviral guidance page: Updated Sept. 4

    by maphere Sep 29, 2014 3:33 PM
    left2rightdoor left2rightdoor Sep 29, 2014 11:38 PM Flag

    The fix is in - peramivir to be approved possibly with subsequent stockpile order, in recognition of asking this small biotech company to turn a significant part of its intellectual assets toward rapid development and evaluation of an Ebola therapy in view of the expanding crisis of health systems in Africa collapsing under the weight of too many patients, too few medical personnel. And when somebody says something about $30 million, remember BARDFA just spent $65 million with a possible $40 adder for adjuvanted influenza vaccine. $100million for untried vaccines, probably translates to $200-$300 milllion for strategic national stockpile of antivirals for pandemic protection.

  • The agency said the Ebola outbreak in West Africa is the largest and most complex to date with over 5,300 reported cases and more than 2,600 deaths.

    Companies invited to submit data to the agency include U.S.-based Biocryst, Canada's Tekmira and France's Fab'entech.

  • left2rightdoor by left2rightdoor Sep 24, 2014 4:51 PM Flag

    Every Bending Phone

  • left2rightdoor by left2rightdoor Sep 24, 2014 3:06 PM Flag

    Peramivir - PDUFA date pending, Barda worried about pandemic influenza
    HAE - have a working drug, improving with second gen for once a day treatment
    BCX 4430 - a drug for more than Ebola, one drug for multiple bugs. MERs, SARS, Marburg etc. IND coming

    positioned like Auxilium for a big pharma, to add multiple pipelines.

  • Underwear For Iphone 5, Underwear For Iphone 5 Suppliers and ...
    wwwdotalibabadotcom › underwear › underwear for
    Underwear For Iphone 5, You Can Buy Various High Quality Underwear For Iphone 5 Products from Global Underwear For Iphone 5 Suppliers and Underwear For Iphone 5 ...Aibaba has just the products needed

  • South China Morning Post man found smuggling 8 iPhones in his underpants.
    (iPhone 6 plus too large.?)

  • Reply to

    Approaching...

    by maphere Sep 22, 2014 2:42 PM
    left2rightdoor left2rightdoor Sep 22, 2014 2:57 PM Flag

    Number 4 -October
    Number 3 November
    Number 2 November before number 3.

  • Solicitation Number:
    BARDA-12-100-SOL-00018
    Notice Type:
    Award Notice
    Contract Award Date:
    September 12, 2014
    Contract Award Number:
    HHSO100201400014C
    Contract Award Dollar Amount:
    Base of $65,949,445; option of $39,849,644
    Contractor Awarded Name:
    Sanofi Pasteur Inc.
    Synopsis:
    Added: Sep 17, 2014 3:00 pm
    Award is for the development of an adjuvanted pandemic influenza vaccine.

    Adjuvants never have been used or approved in US, so peramivir, which has already been used, should be even more attractive than untested adjuvants.

  • Solicitation Number:
    BARDA-12-100-SOL-00018
    Notice Type:
    Award Notice
    Contract Award Date:
    September 12, 2014
    Contract Award Number:
    HHSO100201400014C
    Contract Award Dollar Amount:
    Base of $65,949,445; option of $39,849,644
    Contractor Awarded Name:
    Sanofi Pasteur Inc.
    Synopsis:
    Added: Sep 17, 2014 3:00 pm
    Award is for the development of an adjuvanted pandemic influenza vaccine.

    Contracting Office Address:
    Office of the Assistant Secretary for Preparedness & Response (ASPR)
    Department of Health and Human Services
    330 Independence Ave. SW
    G640
    Washington, District of Columbia 20201
    United States
    Place of Performance:
    Department of Health and Human Services
    Office of the Secretary
    Acquisition Management, Contract and Grants (AMCG)
    330 Independence Avenue, G640

    Washington, District of Columbia 20201
    United States
    Primary Point of Contact.:
    Kevin Nilles,
    Contracting Officer
    kevin.nilles@hhs.gov

  • left2rightdoor left2rightdoor Sep 19, 2014 1:29 PM Flag

    Infect Disord Drug Targets. 2009 Apr;9(2):191-200.
    Drug targets in infections with Ebola and Marburg viruses.
    Gene OG1, Julia BE, Vanessa MR, Victoria WJ, Thomas GW, Lisa HE.
    Author information

    Abstract
    The development of antiviral drugs for Ebola and Marburg viruses has been slow. To date, beyond supportive care, no effective treatments, prophylactic measures, therapies, or vaccines are approved to treat or prevent filovirus infections. In this review, we examine the current treatments available to administer care for filovirus infection, the potential therapeutic targets that can be used for filovirus drug development, and the various drug targeting techniques used against filoviruses.
    PMID: 19275706 [PubMed - indexed for MEDLINE]

  • Reply to

    why is baba not trading?

    by bakhteria Sep 19, 2014 9:38 AM
    left2rightdoor left2rightdoor Sep 19, 2014 9:42 AM Flag

    The NYSE uses a human auction to set the initial price on the day of the IPO and can take between 10 and 75 minutes to determine the initial price, so around 10 it should begin to execute.

  • left2rightdoor by left2rightdoor Sep 19, 2014 3:13 AM Flag

    1. How long after 9:30 for first prices -estimate 9:45 for first price
    2. First price. 78 81 84 ?
    3 Closing price for BABA
    4 Volume traded?

  • Best guess 20-30 minutes after market opens for trading on NYSE

  • left2rightdoor left2rightdoor Sep 17, 2014 2:59 PM Flag

    Continuity of Interest
    The legal doctrine of continuity of interest underlies the principles of tax-free mergers, acquisitions, and reorganizations. Continuity of interest means that a substantial part (not strictly defined, but can vary under the facts and circumstances of the deal) of consideration received in a corporate share transaction is the acquirer's stock. The impact of this requirement is that the seller and its shareholders still have skin in the game as to the success or failure of the surviving enterprise, and are not disinterested parties which have yet realized their investment.

  • Say BABA is 85, Yahoo is 42 1 Baba for 2 Yahoo , and BABA has a. Lot of shares in its pocket, only needs 400-500 million at 2:1 would that be a taxable event for YHOO holders?

  • left2rightdoor by left2rightdoor Sep 14, 2014 10:08 AM Flag

    200 million shares?

  • Reply to

    Mid Sept. funding announcement coming? BCX4430

    by maphere Sep 8, 2014 2:00 PM
    left2rightdoor left2rightdoor Sep 10, 2014 9:17 AM Flag

    WHO fast tracks experimental drugs to fight Ebola New Scientist Sep 9
    More promising might be two wide-spectrum antiviral drugs, BCX4430 and favipiravir. Both resemble the nucleotide molecules that make up the virus's RNA genome, and fool the virus's RNA-copying enzyme – but not a human's – into using them, crippling viral replication

  • left2rightdoor left2rightdoor Sep 9, 2014 6:22 PM Flag

    There seems to be a news blackout about the Working group on experimental Ebola drugs being headed up by Asst Secty for Preparedness Dr. Nicole Lurie, ie, they don't want to indicate panic, but inside the beltway,
    at Fort Belvoir, down in Atlanta, they're in a panic. Time to batten down the hatches, and that means buy up and fund everything that might be an MCM for the EEP (Exponential Ebola Pandemic).

    From a Sep 3 story-ready to increase from 25 to 40 million.
    Mapp Biopharmaceutical has landed an 18-month, $24.9 million contract with the Department of Health and Human Services to further develop ZMapp, an antibody drug designed to treat the Ebola virus.
    HHS’ Biomedical Advanced Research and Development Authority will provide financial, preclinical and manufacturing support to Mapp with the goal of obtaining U.S. regulatory approval for the Ebola medicine, HHS said Tuesday.
    The agency says it could increase ZMapp project funding up to $42.3 million.
    “Developing drugs and vaccines to protect against Ebola as a biological threat has been a long-term goal of the U.S. government, and today’s agreement represents an important step forward,” said Dr. Nicole Lurie, HHS assistant secretary for preparedness and response.
    BARDA plans to collaborate with the National Institute of Allergy and Infectious Diseases, Defense Department and National Institutes of Health to expedite drug development.

YHOO
40.32-0.43(-1.06%)4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.